Latest profit is below market sentiments, which is why the stock price became top underperformer on Sensex ending at Rs450.55 per piece down 1.85%.
Q4 PAT was hampered due to an exceptional item of Rs260.44cr recorded by Sun Pharma.
However, the company saw healthy business as its consolidated revenue rose by 14.67% to Rs8,078.03cr for the period compared to Rs7,044.26cr in Q4FY19.
For FY20, Sun Pharma's consolidated net profit and revenue stand at Rs3,764.93cr and Rs32,325.17cr respectively.
In its financial audit report, Sun Pharma said, "The Group continues to monitor the impact of Covid-19 on its business, including its impact on customers, supply-chain, employees and logistics."
In its meeting held on Wednesday, the company's board recommended payment of a final dividend of Re1 per equity share for FY20 subject to shareholders approval at the ensuing Annual General Meeting. The dividend is expected to be paid during September 2020.